product revenue
The latest news about product revenue: headlines, AI summaries and the full story from every source.
- Medexus Pharmaceuticals Reports Record Q2 Revenue and Net Income Amid GRAFAPEX™ Growth
- Precipio Reports Q3 2026 Revenue Growth Driven by Product Segment Expansion
- Kura Oncology Reports Q3 Revenue Growth for Komzitfi and Outlines Future Clinical Milestones
- Roivant Sciences Reports Q2 2026 Results with LISRAYA Commercial Launch and Positive Clinical Data
- PowerFleet Reports Record Q2 2027 Revenue and Affirms Full-Year Guidance
- NetScout Reports Q2 2027 Results with Margin Expansion and Reaffirmed Guidance
- Iovance Biotherapeutics Reports Q3 Revenue Growth of 80% and EPS Beat
- UroGen Pharma Reports 35% Sequential Revenue Growth for ZUSDURI in Q3 2026
- Ardelyx Reports Q3 2026 Revenue Growth and Narrowing Net Loss
- Check Point Software Technologies Projects 2027 Subscription Revenue Growth and Provides Q4 Guidance
- Alnylam Pharmaceuticals Projects $4.2B–$4.5B in 2026 TTR Sales Amid Q3 Revenue Growth
- Snowflake Provides FY2027 Product Revenue Guidance of $6.07 Billion with AI-Driven Growth
- Autolus Reports Q1 2026 Earnings with Strong Revenue Growth
- Kopin Reports Q1 2026 Earnings with Mixed Revenue Performance
- Arlo Reports Record Q1 Revenue of $150.4M with Strong Growth in Subscriptions
- Fabrinet Reports Q3 2025 Earnings with Revenue Growth and Mixed Segment Performance
- Dolby (DLB) Reports Q3 2025 Earnings with Revenue Growth and Strong Financial Performance
- Check Point Software Technologies Q1 2026 Earnings Call Summary
- Cerus Reports Strong Q1 Earnings and Raises 2026 Revenue Guidance
- Ardelyx Reports Q1 2026 Earnings with Revenue Growth and Guidance Reiteration
- Alnylam Pharmaceuticals Reports Strong Q1 2026 Earnings with Record Revenue
- F5 Announces FY 2026 Revenue Growth Guidance and EPS Outlook
- F5 Networks (FFIV) Reports Q2 2026 Earnings Results
- A10 Networks Reports Q1 2026 Earnings with Revenue Growth and Margin Stability
- West (WST) Reports Strong Q1 2026 Earnings with Revenue and EPS Growth
- Amarin (AMRN) Reports Q2 2025 Earnings with Mixed Revenue Results
- ROC Reports 24% Total Revenue Growth and 58% Product Revenue Growth, Completes Nasdaq IPO